Long-term anti-TNFα therapy for ankylosing spondylitis in two patients with chronic HBV infection

Clinical Rheumatology

Volumn 26, Issue 6, 2007, Pages 950-952

  Sakellariou, Grigorios T ^a   Chatzigiannis, Ioannis ^a  

^a St Paul's Hospital   (Greece)

Author keywords

Ankylosing spondylitis; Etanercept; Hepatitis B; Infliximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANKYLOSING SPONDYLITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHRONIC HEPATITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; HEPATITIS B; HUMAN; LIVER FUNCTION TEST; LONG TERM CARE; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT; VIRUS ACTIVATION; VIRUS LOAD;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HEPATITIS B, CHRONIC; HUMANS; IMMUNOGLOBULIN G; LIVER FUNCTION TESTS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; REMISSION INDUCTION; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34250729244     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-006-0392-1     Document Type: Article

References (11)

1. Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: Hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63(Suppl 2):iI18-ii24
2. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW et al (2005) Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 64(Suppl 4):iV2-iv14
3. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV (1996) Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4:25-36
4. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686-687
5. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM et al (2004) Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 31:107-109
6. Wendling D, Auge B, Bettinger D, Lohse A, Le Huede G, Bresson-Hadni S et al (2005) Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 64:788-789
7. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L (2006) Safety of anti-TNFα therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) (in press)
8. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: Need for primary prophylaxis. Gut 53:1363-1365
9. Ueno Y, Tanaka S, Shimamoto M, Miyanaka Y, Hiyama T, Ito M et al (2005) Infliximab therapy for Crohn's disease in a patient with chronic hepatitis. B Dig Dis Sci 50:163-166
10. del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R (2004) Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 10:701-702
11. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W (2006) Subfulmitant hepatitis B after infliximab in Crohn's disease: Need for HBV-screening? World J Gastroenterol 12:974-976